Safety and complications of continuation of aspirin therapy in patients undergoing robot-assisted laparoscopic simple prostatectomy
Journal of Robotic Surgery · 2024
DOI: 10.1007/s11701-024-01946-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Robotic Surgery, 2024. Verfasst von Sumit Saini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Atrium Health Wake Forest Baptist Medical Center, 140 Charlois Boulevard, Winston-Salem, NC, 27103, USA. Hauptthemen laut MEDLINE: Prostatectomy, Aspirin, Robotic Surgical Procedures, Laparoscopy. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wake Forest University.
Abstract (Originalsprache)
To evaluate the safety and feasibility of continued perioperative aspirin at the time of robotic assisted simple prostatectomy (RASP). We performed a retrospective review of our IRB approved institutional database of patients who underwent RASP between 2013 and 2022. Comparative groups included patients taking aspirin in the perioperative period and those not taking aspirin pre-operatively. The primary outcome was any post-operative bleeding related complication using the modified Clavien–Dindo classification. Secondary outcomes included the identification of risk factors for increased blood loss in the entire study population, operative time, and blood transfusion requirement. 143 patients underwent RASP of which 55 (38.5%) patients continued perioperative aspirin therapy and 88 (61.5%) patients did not. Baseline demographics were similar between groups. Patients taking perioperative aspirin had a higher rate of hypertension (74.5% vs 58.0%, p = 0.04) and other cardiovascular disease (30.9% vs 11.4%, p = 0.007). Postoperative complications were similar between the groups (Clavien-Dindo ≥ 3; p = 0.43). Median blood loss (150 cc vs 150 cc, p = 0.38), percentage drop in hemoglobin (13.4 vs 13.2, p = 0.94) and blood transfusion rate (3.6 vs 1.1, p = 0.56) were also similar between groups. The median blood loss was 150 ml for the whole study population. On regression analysis, neither aspirin nor any other variable was associated with increased blood loss (> 150 ml). Aspirin can be safely continued perioperatively in patients undergoing RASP without any risk of bleeding related complications, blood loss, or increased transfusion rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Atrium Health Wake Forest Baptist Medical Center, 140 Charlois Boulevard, Winston-Salem, NC, 27103, USA.
- Department of Urology, Atrium Health Wake Forest Baptist Medical Center, 140 Charlois Boulevard, Winston-Salem, NC, 27103, USA. pthakker@wakehealth.edu.
Förderung
- Wake Forest University
Zitieren
APA
Saini, S., Thakker, P. U., Ritts, R., O'Rourke, T. K., & Hemal, A. K. (2024). Safety and complications of continuation of aspirin therapy in patients undergoing robot-assisted laparoscopic simple prostatectomy. Journal of Robotic Surgery. https://doi.org/10.1007/s11701-024-01946-2
Vancouver
Saini S, Thakker PU, Ritts R, O'Rourke TK, Hemal AK. Safety and complications of continuation of aspirin therapy in patients undergoing robot-assisted laparoscopic simple prostatectomy. Journal of Robotic Surgery. 2024. doi:10.1007/s11701-024-01946-2
BibTeX
@article{Saini2024,
author = {Saini, Sumit and Thakker, Parth U and Ritts, Rory and O'Rourke, Timothy K and Hemal, Ashok K},
title = {Safety and complications of continuation of aspirin therapy in patients undergoing robot-assisted laparoscopic simple prostatectomy},
journal = {Journal of Robotic Surgery},
year = {2024},
doi = {10.1007/s11701-024-01946-2}
}
EUVIMED